GW9508

Name: GW9508
Brand: MedChemExpress
SKU: HY-15589
Rating: 5.0 (7 reviews)

Cat. No.: HY-15589 Purity: 99.23%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

GW9508 is a potent and selective G protein-coupled receptors FFA1 (GPR40) and GPR120 agonist with pEC₅₀s of 7.32 and 5.46, respectively. GW9508 shows ~100-fold selectivity for GPR40 over GPR120. GW9508 is inactive against other GPCRs, kinases, proteases, integrins and PPARs. GW9508 is a glucose-sensitive insulin secretagogue and an ATP-sensitive potassium (K_ATP) channels opener. Anti-inflammatory and anti-atherosclerotic activities.

For research use only. We do not sell to patients.

CAS No. : 885101-89-3

Size	Stock	Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
200 mg	Get quote
500 mg	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 7 publication(s) in Google Scholar

Other Forms of GW9508:

GW9508 (Standard) In-stock

7 Publications Citing Use of MCE GW9508

•Bioengineering (Basel). 2023 Apr 27;10(5):535.

Histological Imaging/Staining

Cell Imaging/Staining

Others

ELISA

: GW9508 purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 May 1:116971. [Abstract]; Dihydroergotamine (DHE) staining was performed on the control group (ctr), GW9508 (10 μM; 12 h) group, GW9508 + GW1100 group, Hb group, Hb + GW9508 group, and Hb + GW9508 + GW1100 group. Scale bar = 20 μm. Arrows indicate the production of superoxide anions.

: GW9508 purchased from MedChemExpress. Usage Cited in: Biochem Pharmacol. 2025 May 1:116971. [Abstract]; Representative Western blot plots of cleaved IL-1β and CD63 expression in the control group (ctr), GW9508 (10 μM; 12 h) group, GW9508 + GW1100 group, SAH group, SAH + GW9508 group and SAH + GW9508 + GW1100 group.

: GW9508 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Oct 10;43(10):114858. [Abstract]; GW9508 (100 μg). Representative images of hematoxylin-eosin (H&E), safranin O-fast green (S&F), and TRAP staining of forepaw ankle joint sections.

: GW9508 purchased from MedChemExpress. Usage Cited in: Cell Rep. 2024 Oct 10;43(10):114858. [Abstract]; The levels of anti-collagen II IgM, IgG and IgA antibodies in the serum of mice treated with GW1100 and GW9508 (100 μg) after CIA induction.

: GW9508 purchased from MedChemExpress. Usage Cited in: Int J Mol Sci. 2023 Mar 18;24(6):5801.; Effect of AH-7614, AdipoRon, and AH-7614 + AdipoRon on calcium responses to 30 µM LA, and effect of AdipoRon on calcium responses to the GPR120 agonist GW9805 (10 µM).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Free Fatty Acid Receptor Isoform Specific Products:

View All Isoforms

FFAR1 FFAR2 FFAR3 FFAR4

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

pEC50: 7.32 (GPR40) and 5.46 (GPR120)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
CHO	EC₅₀	13 nM Compound: GW 9508	Agonist activity at human GPR40 expressed in CHO cells by calcium flux assay Agonist activity at human GPR40 expressed in CHO cells by calcium flux assay	[PMID: 24835985]
CHO	EC₅₀	99 nM Compound: GW 9508	Agonist activity at rat GPR40 expressed in CHO cells by calcium flux assay Agonist activity at rat GPR40 expressed in CHO cells by calcium flux assay	[PMID: 24835985]
HEK293	EC₅₀	1.2 μM Compound: 2, GW-9508	Agonist activity at human GPR40 H86F mutant expressed in HEK-EM 293 cells assessed as increase in intracellular calcium Agonist activity at human GPR40 H86F mutant expressed in HEK-EM 293 cells assessed as increase in intracellular calcium	[PMID: 17552505]
HEK293	EC₅₀	17.8 μM Compound: 2, GW-9508	Agonist activity at human GPR40 N244A mutant expressed in HEK-EM 293 cells assessed as increase in intracellular calcium Agonist activity at human GPR40 N244A mutant expressed in HEK-EM 293 cells assessed as increase in intracellular calcium	[PMID: 17552505]
HEK293	EC₅₀	2.2 μM Compound: 2, GW-9508	Agonist activity at human GPR40 H86A mutant expressed in HEK-EM 293 cells assessed as increase in intracellular calcium Agonist activity at human GPR40 H86A mutant expressed in HEK-EM 293 cells assessed as increase in intracellular calcium	[PMID: 17552505]
HEK293	EC₅₀	6.8 μM Compound: 2, GW-9508	Agonist activity at human GPR40 H137F mutant expressed in HEK-EM 293 cells assessed as increase in intracellular calcium Agonist activity at human GPR40 H137F mutant expressed in HEK-EM 293 cells assessed as increase in intracellular calcium	[PMID: 17552505]
HEK293	EC₅₀	> 30 μM Compound: 2, GW-9508	Agonist activity at human GPR40 H137A mutant expressed in HEK-EM 293 cells assessed as increase in intracellular calcium Agonist activity at human GPR40 H137A mutant expressed in HEK-EM 293 cells assessed as increase in intracellular calcium	[PMID: 17552505]

In Vitro

GW9508 stimulates intracellular Ca²⁺ mobilization in HEK-293 cells expressing GPR40 (pEC₅₀ of 7.32) or GPR120 (pEC₅₀ of 5.46), but not in the parent HEK-293 cell line^[1].
GW9508 produces a concentration-dependent increase (pEC₅₀ of 6.14) in glucose-stimulated insulin secretion at high glucose levels (25 mM). This resulted in a 1.52-fold increase in insulin secretion with 20 μM GW9508 in the presence of 25 mM glucose, compared with 25 mM glucose alone. The ability of GW9508 (10 μM) to enhance insulin secretion from MIN6 cells is significantly enhanced as glucose concentrations are increased^[1].
GW9508 inhibits CCL17 and CCL5 expression in a pertussis toxin-sensitive manner. The inhibitory effect by GW9508 is abrogated by depletion of GPR40 with RNA interference. GW9508 further suppresses expression of IL-11, IL-24, and IL-33 induced in HaCaT cells by TNF-α and IFN-γ. GW9508 also inhibits CCL5 and CXCL10 production by normal human epidermal keratinocytes^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Administration of GW9508 200 (μM) topically to the skin suppresses ear swelling in a repeated hapten application model (BALB/c and C57BL/6 mice) and contact hypersensitivity with downregulation of CCL5 and CXCL10, respectively^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

347.41

Formula

C₂₂H₂₁NO₃

CAS No.

885101-89-3

Appearance

Solid

Color

White to off-white

SMILES

O=C(O)CCC1=CC=C(NCC2=CC=CC(OC3=CC=CC=C3)=C2)C=C1

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (287.84 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8784 mL	14.3922 mL	28.7844 mL
5 mM	0.5757 mL	2.8784 mL	5.7569 mL
10 mM	0.2878 mL	1.4392 mL	2.8784 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.20 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.23%

Select Batch:

Data Sheet (273 KB) SDS (620 KB)

COA (244 KB) HNMR (157 KB) LCMS (106 KB)

Handling Instructions (2659 KB)

References

[1]. Briscoe CP, et al. Pharmacological regulation of insulin secretion in MIN6 cells through the fatty acid receptor GPR40: identification of agonist and antagonist small molecules. Br J Pharmacol. 2006 Jul;148(5):619-28. [Content Brief]

[2]. Fujita T, et al. A GPR40 agonist GW9508 suppresses CCL5, CCL17, and CXCL10 induction in keratinocytes and attenuates cutaneous immune inflammation. J Invest Dermatol, 2011, 131(8), 1660-1667. [Content Brief]

[3]. Zhao YF, et al. Activation of ATP-sensitive potassium channels in rat pancreatic beta-cells by linoleic acid through both intracellular metabolites and membrane receptor signalling pathway. J Endocrinol, 2008, 198(3), 533-540. [Content Brief]

[4]. Suski M, et al. Anti-atherosclerotic action of GW9508 - Free fatty acid receptors activator - In apoE-knockout mice. Pharmacol Rep. 2019 Aug;71(4):551-555. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8784 mL	14.3922 mL	28.7844 mL	71.9611 mL
	5 mM	0.5757 mL	2.8784 mL	5.7569 mL	14.3922 mL
	10 mM	0.2878 mL	1.4392 mL	2.8784 mL	7.1961 mL
	15 mM	0.1919 mL	0.9595 mL	1.9190 mL	4.7974 mL
	20 mM	0.1439 mL	0.7196 mL	1.4392 mL	3.5981 mL
	25 mM	0.1151 mL	0.5757 mL	1.1514 mL	2.8784 mL
	30 mM	0.0959 mL	0.4797 mL	0.9595 mL	2.3987 mL
	40 mM	0.0720 mL	0.3598 mL	0.7196 mL	1.7990 mL
	50 mM	0.0576 mL	0.2878 mL	0.5757 mL	1.4392 mL
	60 mM	0.0480 mL	0.2399 mL	0.4797 mL	1.1994 mL
	80 mM	0.0360 mL	0.1799 mL	0.3598 mL	0.8995 mL
	100 mM	0.0288 mL	0.1439 mL	0.2878 mL	0.7196 mL

GW9508 Related Classifications

Metabolic Disease Inflammation/Immunology Cardiovascular Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

GW9508

Customer Review

Other Forms of GW9508:

GW9508 Related Antibodies

7 Publications Citing Use of MCE GW9508

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Free Fatty Acid Receptor Isoform Specific Products:

Biological Activity

Purity & Documentation

References

Customer Review

GW9508 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

GW9508 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report